Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
06 déc. 2022 01h00 HE
|
Kinarus Therapeutic Holding AG
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report...
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
22 nov. 2022 01h00 HE
|
Kinarus Therapeutic Holding AG
Method-of-use-patent covers KIN001 in ophthalmic diseasesFurther strengthens already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November 2022. Kinarus Therapeutics...
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
16 nov. 2022 01h00 HE
|
Kinarus Therapeutic Holding AG
Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunitiesMultiple opportunities for KIN001 in indications with high unmet need are...
Kinarus Therapeutics Provides Strategic Update
04 nov. 2022 02h00 HE
|
Kinarus Therapeutic Holding AG
Exploring financial and strategic options to fund Phase 2 trials of KIN001 in wet age-related macular degeneration and idiopathic pulmonary fibrosisKINFAST phase 2 clinical trial of KIN001 in mild to...
Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety
30 sept. 2022 01h00 HE
|
Kinarus Therapeutic Holding AG
KINETIC, a Phase 2 clinical study of KIN001, an oral drug combination, to be discontinued following recommendation of the DSMBKIN001 was shown to be safe and well toleratedEnrollment in the Phase 2...
Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update
31 août 2022 01h00 HE
|
Kinarus Therapeutic Holding AG
Interim data from Phase 2 KINETIC clinical trial of KIN001 to treat hospitalized COVID-19 patients expected in Q3 2022First patient dosed with in Phase 2 KINFAST clinical trial with ambulatory...
Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients
29 août 2022 01h00 HE
|
Kinarus Therapeutic Holding AG
KINFAST to evaluate ability of KIN001 to reduce severity and duration of symptoms in ambulatory COVID-19 patientsInterim data from ongoing Phase 2 KINETIC trial in hospitalized Covid-19 patients...
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
22 août 2022 01h05 HE
|
Kinarus Therapeutic Holding AG
KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanismsPhase 2 trials of KIN001 in hospitalized and ambulatory COVID-19 patients ongoingInterim data from Phase 2...
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville
22 août 2022 01h00 HE
|
Kinarus Therapeutic Holding AG
Financing to be drawn in tranchesFinancing will enable Kinarus to advance the clinical development of KIN001 Basel, Switzerland, August 22, 2022. Kinarus Therapeutics Holding AG (SIX: KNRS)...